PER 0.00% 10.5¢ percheron therapeutics limited

Ann: New Indication for ATL1102 Limb Girdle Muscular Dystrophy R2, page-40

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 4,365 Posts.
    lightbulb Created with Sketch. 2034
    This also supports the DMD trial, with more data showing how ATL1102 is effective against cd49 over expression. This is what we need.

    This controlling of cd49 is why ATL1102 is becoming a platform drug. The inflammation caused by the over expression of cd49 is becoming to be seen as one of the root causes to many diseases. Controlling this allows the body a chance of repairing itself. This can be seen by the reduction of fat tissue in muscle of the DMD boy group. And also the reduction of brain lesions in theMS trial group.
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
10.5¢
Change
0.000(0.00%)
Mkt cap ! $94.66M
Open High Low Value Volume
10.5¢ 10.5¢ 9.8¢ $58.09K 574.8K

Buyers (Bids)

No. Vol. Price($)
1 38503 10.0¢
 

Sellers (Offers)

Price($) Vol. No.
10.5¢ 194063 5
View Market Depth
Last trade - 16.10pm 04/10/2024 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.